Search results for "Nausea"

showing 10 items of 138 documents

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

Giant hepatocellular adenoma as cause of severe abdominal pain: a case report

2007

Abstract The authors describe the case of a large hepatocellular adenoma diagnosed in a 30-year old woman who came to us complaining of acute pain in the upper abdominal quadrants. The patient had been taking an oral contraceptive pill for the last ten years. We present the clinical features, the diagnostic work-up and the treatment prescribed.

Abdominal painPathologyoral contraceptive agent EMTREE medical terms: abdominal painanamnesilcsh:Medicinecomputer assisted tomographyaspartate aminotransferaseSurgical oncologynuclear magnetic resonance imagingMedicine(all)oral contraceptionadultarticleGeneral MedicineAbdominal quadrantsfemalepriority journalhistopathologycontrast enhancementdisease severitymedicine.symptomEMTREE drug terms: alanine aminotransferasemedicine.medical_specialtyOral contraceptive pillcontrast mediummedicinediffusion weighted imagingcase reportfollow uphumanAcute painliver biopsydrug useliver lobectomybusiness.industryGeneral surgeryPublic healthlcsh:RechographyHepatocellular adenomaliver angiographymedicine.diseasetumor bleedinghuman tissueclinical featurenausea and vomitingbusinessaspartate aminotransferase blood levelliver adenomaalanine aminotransferase blood level
researchProduct

Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

2014

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

AdultComplementary TherapiesMalemedicine.medical_specialtyBenzylaminesAdolescentNauseaUrologyNaphthalenesDapoxetine Safety Cardiovascular events SyncopeSyncopeCardiovascular eventsYoung AdultInternal medicinePremature ejaculationmedicine80 and overCardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young AdultHumansProspective StudiesPremature EjaculationAdverse effectProspective cohort studyCardiovascular events; Safety; DapoxetineAgedCardiovascular events; Dapoxetine; Safety; Syncope; UrologyAged 80 and overSertralinebusiness.industrySettore MED/24 - UROLOGIAIncidence (epidemiology)Cardiovascular events; Dapoxetine; Safety; Syncope; Adolescent; Adult; Aged; Aged 80 and over; Benzylamines; Complementary Therapies; Humans; Male; Middle Aged; Naphthalenes; Premature Ejaculation; Prospective Studies; Serotonin Uptake Inhibitors; Young Adult; UrologyMiddle AgedDapoxetineCardiovascular events; Dapoxetine; syncope; SafetyDapoxetineAnesthesiaSerotonin Uptake InhibitorsObservational studymedicine.symptomSafetybusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugCardiovascular events Dapoxetine Safety Syncope
researchProduct

Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…

2009

Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…

AdultDiarrheaMalemedicine.medical_specialtyNeutropeniaTime FactorsEsophageal NeoplasmsCetuximabPhases of clinical researchKaplan-Meier EstimateAntibodies Monoclonal Humanizedmedicine.disease_causeGastroenterologyDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalAgedCross-Over StudiesDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalNauseaHematologyMiddle AgedCombined Modality TherapySurvival AnalysisChemotherapy regimenSurgeryTreatment OutcomeOncologyEpidermoid carcinomaFluorouracilResponse Evaluation Criteria in Solid TumorsCarcinoma Squamous CellFemaleFluorouracilKRASCisplatinbusinessFollow-Up Studiesmedicine.drugAnnals of Oncology
researchProduct

Is ‘anxiety sensitivity’ predictive of postoperative nausea and vomiting?

2019

BACKGROUND Postoperative nausea and vomiting (PONV) is an extremely distressing side effect for patients. Despite PONV prophylaxis guided by well established scoring systems, the incidence of PONV is still high. OBJECTIVE The aim of the current study was to investigate the predictive value of anxiety sensitivity as an additional independent risk factor for PONV in patients with an increased risk of PONV. DESIGN A noninterventional, observational study. SETTING A tertiary care university hospital. PATIENTS Patients with an increased risk of PONV (i.e. female, nonsmoking) undergoing elective surgery (general, gynaecological, urological, musculoskeletal or neurosurgical) under general anaesthe…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentAnesthesia GeneralAnxietyRisk AssessmentPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineGeneral anaesthesiaProspective StudiesRisk factorElective surgeryAgedPsychological Testsbusiness.industryIncidenceAge FactorsOdds ratioMiddle AgedPrognosisAnesthesiology and Pain MedicineElective Surgical ProceduresPostoperative Nausea and VomitingAnxiety sensitivityAntiemeticsFeasibility StudiesFemaleObservational studymedicine.symptombusinessPostoperative nausea and vomitingEuropean Journal of Anaesthesiology
researchProduct

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer

2019

Abstract Background and objectives Pre-clinical data have shown that combining trifluridine/tipiracil with oxaliplatin enhances anti-tumour activity compared with either monotherapy. A phase I dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended dose (RD) for phase II and pharmacokinetic profile of this combination in patients with metastatic colorectal cancer (mCRC) who had progressed after at least 1 prior line of treatment. Methods Using a 3 + 3 design, patients received escalating trifluridine/tipiracil doses from 25, then 30 and to 35 mg/m2 twice daily, days 1–5, q14 days, together with a fixed dose of 85 mg/m2 of oxaliplatin day 1, q14 days. A…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPyrrolidinesMaximum Tolerated DoseNauseaTrifluridineNeutropeniaGastroenterologyTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineUracilAdverse effectneoplasmsAgedTipiracilbusiness.industryMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisVomitingFemalemedicine.symptomColorectal NeoplasmsbusinessThymineFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

A Phase I–II Study on the Toxicity and Therapeutic Efficacy of 5-Fluorouracil in Combination with Leucovorin and Cisplatinum in Patients with Advance…

1990

5-Fluorouracil (5-FU) has been the treatment of choice for colorectal carcinoma with an overall response rate of about 20%. Recent studies have shown that folate (LV) can increase 5-FU therapeutic efficacy, achieving about a 40% response rate without a clear impact on survival. Cisplatinum (CDDP) is usually inactive in colorectal carcinoma, but the association with 5-FU results in a synergistic antineoplastic effect. A phase I-II study was done to assess the maximally tolerated dose (MTD) of CDDP in association with 5-FU + LV. The MTD for CDDP was 20 mg/m2/wk in association with 5-FU 400-500 mg/m2/wk and LV 500 mg/m2/wk. WHO criteria were used for evaluation of both toxicity and response. I…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerNausea030106 microbiologyLeucovorinGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicinePharmacology (medical)In patientAgedPharmacologyCisplatinClinical Trials as Topicbusiness.industryMiddle Agedmedicine.diseaseDiarrheaInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityVomitingDrug EvaluationFemaleFluorouracilCisplatinmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct

The latent structure of the functional dyspepsia symptom complex: A taxometric analysis

2016

OBJECTIVES: Rome III introduced a subdivision of functional dyspepsia (FD) into postprandial distress syndrome and epigastric pain syndrome, characterized by early satiation/postprandial fullness, and epigastric pain/burning, respectively. However, evidence on their degree of overlap is mixed. We aimed to investigate the latent structure of FD to test whether distinguishable symptom-based subgroups exist. METHODS: Consecutive tertiary care Rome II FD patients completed the dyspepsia symptom severity scale. Confirmatory factor analysis (CFA) was used to compare the fit of a single factor model, a correlated three-factor model based on Rome III subgroups and a bifactor model consisting of a g…

AdultMaleAbdominal painAdolescentPhysiologyEpigastric painYoung Adult03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesmedicineHumansDyspepsiaLatent structureAgedAged 80 and overTertiary HealthcareEndocrine and Autonomic Systemsbusiness.industrySingle factorGastroenterologyNauseaMiddle AgedClassificationPostprandial Periodmedicine.diseaseRome iiiConfirmatory factor analysisAbdominal PainDistress030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologymedicine.symptombusinessSomatizationClinical psychology
researchProduct

A Randomized, Blinded, Prospective Trial to Compare the Safety and Efficacy of Three Bowel-Cleansing Solutions for Colonoscopy (HSG-01*)

2003

BACKGROUND AND STUDY AIMS There are conflicting data regarding the optimal bowel preparation for colonoscopy. This study was carried out to compare the efficacy, safety, and tolerability of three widely used bowel lavage solutions: the standard polyethylene glycol-electrolyte solution based on the GoLytely formulation (PEG-EL1; Klean-Prep); a sulphate-free PEG-EL solution based on the NuLytely formulation (PEG-EL2, Endofalk); and a sodium phosphate preparation (NaP, Fleet Phospho-Soda). PATIENT AND METHODS A total of 185 consecutive patients scheduled for elective colonoscopy were prospectively randomly assigned to undergo pre-colonoscopic bowel cleansing with either 4 l of PEG-EL1 (n=64), …

AdultMaleAbdominal painmedicine.medical_specialtyRandomizationAdolescentNauseaRectumColonoscopyPhosphatesPolyethylene GlycolsElectrolytesPatient satisfactionmedicineHumansAscending colonProspective StudiesAgedmedicine.diagnostic_testCatharticsbusiness.industryGastroenterologyColonoscopyMiddle AgedSurgerySolutionsmedicine.anatomical_structureTolerabilityFemalemedicine.symptombusinessEndoscopy
researchProduct

Comparison of Ondansetron versus Clonidine efficacy for prevention of postoperative pain, nausea and vomiting after orthognathic surgeries : a triple…

2018

Background The aim of this randomized controlled triple blind trial was to compare the efficacy of clonidine with dexamethasone versus ondansetron with dexamethasone for postoperative pain, nausea and vomiting prevention in orthognathic surgery patients. Material and Methods In this clinical trial study, 30 consecutive patients with skeletal class III deformities were candidates for orthognathic surgery in Qaem hospital, Mashhad University of medical sciences, Mashhad, Iran from March to November 2017. These subjects were randomly assigned to two equal number groups, ondansetron or clonidine. Patients received either oral ondansetron 8mg or oral clonidine 150μg as premedication, 1 hour befo…

AdultMaleAdolescentNauseamedicine.medical_treatmentOrthognathic surgeryClonidinelaw.inventionOndansetron03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind Method030202 anesthesiologylawmedicineHumansGeneral DentistryDexamethasoneAnalgesicsPain Postoperativebusiness.industryOrthognathic Surgical ProceduresResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]OndansetronClonidineTreatment OutcomeOtorhinolaryngologyAnesthesiaPostoperative Nausea and VomitingUNESCO::CIENCIAS MÉDICASVomitingAntiemeticsSurgeryPremedicationFemalemedicine.symptomOral Surgerybusinessmedicine.drug
researchProduct